JMP Securities analyst Jason Butler reiterated a Buy rating on Pfenex (PFNX) yesterday and set a price target of $13. The company’s shares closed yesterday at $4.89.
According to TipRanks.com, Butler is a 5-star analyst with an average return of 15.1% and a 52.0% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Adamas Pharmaceuticals, and Axovant Gene Therapies.
Pfenex has an analyst consensus of Moderate Buy, with a price target consensus of $13, a 165.8% upside from current levels. In a report released yesterday, William Blair also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.42 and a one-year low of $3.13. Currently, Pfenex has an average volume of 93.66K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfênex, Inc. is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.
